{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"free of disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"isolated locoregional progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"isolated distant progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"both locoregional and distant progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"no evidence of disease, died of comorbid illness"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Patients with locoregional and/or distant progression","groups":[{"description":"erlotinib + celecoxib: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression","id":"OG000","title":"Erlotinib + Celecoxib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"20 months","title":"Locoregional Progression","type":"SECONDARY","unitOfMeasure":"participants"}